Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam

Abstract

In lieu of an abstract, here is the article\u27s first paragraph: \u22A global crisis of antibiotic resistance is ongoing, especially with resistant gram-negative pathogens including Pseudomonas spp, carbapenemase-producing Enterobacteriaceae, and extended-spectrum β-lactamase (ESBL)-producing organisms. The increasing rate of methicillin-resistant Staphylococcus aureus (MRSA) infections is also a concern.1 One newer intravenous cephalosporin (ceftaroline) was approved in 2010, and 2 new intravenous cephalosporin–β-lactamase inhibitor combinations (ceftolozane-tazobactam and ceftazidime-avibactam) have recently been approved to try to combat these resistant organisms in adult patients.\u2

Global Trends of Antimicrobial Susceptibility of Ceftaroline and Ceftazidime-Avibactam: A Surveillance Study from the ATLAS Program (2012-2016)

“…On the other hand, ceftazidime-avibactam showed susceptibility >90% against Gram-negative bacteria including Enterobacteriaceae, Pseudomonas aeruginosa and Proteus mirabilis, with overtly increased antimicrobial activity observed from the addition of avibactam to ceftazidime.Further analysis of data in China showed that similar to the global pattern, the susceptibilities ofEscherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosato ceftazidime-avibactam were high (92.9%-99.0%)in China. Those results are generally similar with those of surveillance studies in China, 18 Asia 19 the United States, [20][21][22] and Europe, 23 and from the AWARE surveillance program, [24][25][26] but with some minute differences that could be due to the specimens' area of origin, since the present study includedspecimens from all over the world. Another source of difference could be the tested period since bacterial susceptibility changes over time.…”

Global trends of antimicrobial susceptibility of ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)

“…On the other hand, ceftazidime-avibactam showed susceptibility >90% against Gram-negative bacteria including Enterobacteriaceae, Pseudomonas aeruginosa and Proteus mirabilis, with overtly increased antimicrobial activity observed from the addition of avibactam to ceftazidime.Further analysis of data in China showed that similar to the global pattern, the susceptibilities ofEscherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosato ceftazidime-avibactam were high (92.9%-99.0%)in China. Those results are generally similar with those of surveillance studies in China, 18 Asia 19 the United States, [20][21][22] and Europe, 23 and from the AWARE surveillance program, [24][25][26] but with some minute differences that could be due to the specimens' area of origin, since the present study includedspecimens from all over the world. Another source of difference could be the tested period since bacterial susceptibility changes over time.…”

Global trends of antimicrobial susceptibility of ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)

“…Those results are generally similar with those of surveillance studies in China, 18 Asia, 19 the United States of America, [20][21][22] and Europe, 23 and with the AWARE surveillance program, [24][25][26] but with some minute differences that could be due to the specimens' area of origin since the present study includedspecimens from all over the world. Another source of difference could be the tested period since bacterial susceptibility changes over time.…”